48 results on '"JONES, BRIAN"'
Search Results
2. Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
3. Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
4. SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
5. Thymoma Associated With Keratoconjunctivitis, Lichen Planus, Hypogammaglobinemia, and Absent Circulating B Cells
6. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer
7. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study
8. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel
9. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
10. Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.
11. Comprehensive molecular profiling of advanced gynecologic malignancies.
12. Genomic analysis of circulating tumor DNA in 442 patients with carcinoma of unknown primary: Implications for targeted therapeutics.
13. Three dimensional organotypic ex vivo culture of tissues from post-operated tumor samples: Strengths and limitations.
14. Personalized, molecularly matched combination therapies for treatment-na.
15. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.
16. Symptoms and health related quality of life in patients receiving matched therapy.
17. Reply to T. Hasegawa et al and I. Gross et al
18. Investigating the Utility of comprehensive genomic Profiling for patients with newly diagnosed breast cancer.
19. Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials.
20. Oncologic outcomes of advanced gynecologic malignancies managed with the aid of comprehensive genomic profiling (CGP) in a rural community setting.
21. Value of sequencing-guided treatment for patients with advanced malignancies.
22. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
23. Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.
24. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
25. HER2 amplification and overexpression between primary and liver metastatic breast cancer: Significance and implication.
26. Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
27. Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis.
28. CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer
29. Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial
30. Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.
31. Frequently deleted genes in ovarian cancer as indicators of platinum response.
32. Prognostic effect of EIF4EBP1 on ovarian cancer: A single gene biomarker for overall survival and platinum response.
33. Effect of pan-PI3K and HER2 blockade on antitumor activity in preclinical models of breast cancer resistance to trastuzumab therapy.
34. A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells.
35. Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development
36. Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer.
37. Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
38. Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients.
39. Association of a compact 13-gene VEGF signature with OS in E2100.
40. Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?
41. Reply to T.H. Oude Munnink et al
42. Whither HER2-Related Therapeutics?
43. Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated
44. Reply to S.M. Ali et al
45. Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
46. Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
47. Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
48. Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.